Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer

Triple-negative breast cancers (TNBC) have poorer outcomes than hormone positive or human epidermal growth factor receptor 2 (HER2)-positive breast cancers, with chemotherapy being the usual standard of care. Veliparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been studied in both breast c...

Descripción completa

Detalles Bibliográficos
Autores principales: Kota, Karthik, Puhalla, Shannon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580965/
https://www.ncbi.nlm.nih.gov/pubmed/28875097
http://dx.doi.org/10.7759/cureus.1424
_version_ 1783260971888803840
author Kota, Karthik
Puhalla, Shannon
author_facet Kota, Karthik
Puhalla, Shannon
author_sort Kota, Karthik
collection PubMed
description Triple-negative breast cancers (TNBC) have poorer outcomes than hormone positive or human epidermal growth factor receptor 2 (HER2)-positive breast cancers, with chemotherapy being the usual standard of care. Veliparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been studied in both breast cancer susceptibility genes 1 and 2 (BRCA)-mutation related and sporadic cancers as a single agent and in combination with chemotherapy. Here, we describe a patient whose metastatic recurrence of TNBC was treated with combination chemotherapy and veliparib followed by maintenance single-therapy veliparib.
format Online
Article
Text
id pubmed-5580965
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-55809652017-09-05 Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer Kota, Karthik Puhalla, Shannon Cureus Oncology Triple-negative breast cancers (TNBC) have poorer outcomes than hormone positive or human epidermal growth factor receptor 2 (HER2)-positive breast cancers, with chemotherapy being the usual standard of care. Veliparib, a poly ADP-ribose polymerase (PARP) inhibitor, has been studied in both breast cancer susceptibility genes 1 and 2 (BRCA)-mutation related and sporadic cancers as a single agent and in combination with chemotherapy. Here, we describe a patient whose metastatic recurrence of TNBC was treated with combination chemotherapy and veliparib followed by maintenance single-therapy veliparib. Cureus 2017-07-04 /pmc/articles/PMC5580965/ /pubmed/28875097 http://dx.doi.org/10.7759/cureus.1424 Text en Copyright © 2017, Kota et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Oncology
Kota, Karthik
Puhalla, Shannon
Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
title Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
title_full Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
title_fullStr Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
title_full_unstemmed Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
title_short Sustained, Long-Term Maintenance of Remission with Single-Agent Veliparib in Recurrent Triple-Negative Breast Cancer
title_sort sustained, long-term maintenance of remission with single-agent veliparib in recurrent triple-negative breast cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5580965/
https://www.ncbi.nlm.nih.gov/pubmed/28875097
http://dx.doi.org/10.7759/cureus.1424
work_keys_str_mv AT kotakarthik sustainedlongtermmaintenanceofremissionwithsingleagentveliparibinrecurrenttriplenegativebreastcancer
AT puhallashannon sustainedlongtermmaintenanceofremissionwithsingleagentveliparibinrecurrenttriplenegativebreastcancer

Ejemplares similares